Keywords
rheumatology
muscular weakness
autoimmune disease
creatine kinase
How to Cite
Abstract
Polymyositis is an autoimmune myopathy and each year it causes 4 cases per million in the worldwide population, it is clinically diagnosed and needs rapid and aggressive treatment because it can lead to fatal outcomes. This pathology is infrequent in men, with a proportion women/men 2.5:1, the objective of the article was to describe and compare with the literature the case of a male patient with polymyositis, who presented with muscle weakness and polyarticular pain of 20 days of evolution, with Creatine kinase values of 24,000 IU/L, associated with weight loss, and responding adequately to the medical treatment provided at the time. After 3 years asymptomatic, he suffered an acute phase that was managed with first-line medications but without improvement, for which he required oral methylprednisolone at high doses and inmunomodulators. At no time did he present vital organ involvement, he is currently symptomatic and is under medical management. MÉD.UIS.2022;35(1):49-56.
References
Kasper D, Fauci A, Hauser S, Longo D, Jameson L, Lozcalz L. Harrison Principios de medicina interna. McGraw-Hill Interamericana Editores, S.A. de C.V, traductor. 19th ed. New York: McGraw-Hill Education; 2015.
Zou Y, Jin W, Li Y. Roles of macrophage migration inhibitory factor in polymyositis: Inflammation and regeneration. J Int Med Res [Internet]. 2018 [citado 2019 Dic 28];46(2):732-8. DOI: https://doi.org/10.1177/0300060517726194.
Bertorini T, Meza K, Chunga N. Miopatías autoinmunes: revisión de diagnóstico y manejo. An Fac med [Internet]. 2019 [citado 2019 Dic 28];80(3):362-371. DOI: https://doi.org/10.15381/anales.803.16274.
Bohan A, Peter J. Polymyositis and Dermatomyositis (First of two parts). N Engl J Med [Internet]. 1975 [citado 2019 Dic 28];292:(7):344-7. DOI: https://doi.org/10.1056/NEJM197502132920706.
Infante Amorós A, Casas Figueredo N, Pérez Campos D, Chico Capote A, Sánchez Bruzón Y, Estévez del Toro M. Fuerza muscular y niveles séricos de fosfocreatincinasa en pacientes con polimiositis y/o dermatomiositis. Rev Cuba Reumatol [Internet]. 2013 [citado 2019 Dic 28]; 15(3):131-138. Disponible en: http://www.revreumatologia.sld.cu/index.php/reumatologia/article/view/263/422.
Irazoque Palazuelos F, Barragán Navarro Y. Epidemiología, etiología y clasificación. Reumatol Clin [Internet]. 2009 [citado 2019 Dic 28]; 5(S3):2–5. DOI: https://doi.org/10.1016/j.reuma.2009.09.007.
Pinto LF, Ángel AM, Bohórquez R, López CM. Caracterización de los pacientes con polimiositis y dermatomiositis del Servicio de Reumatología del Instituto de Seguros Sociales de Medellín, Colombia, 1992-2000. Rev. Colomb. Reumatol. 2003; 10(1):9-18.
Restrepo JF. Dermatomiositis-polimiositis. Rev. Colomb. Reumatol [Internet]. 2003 [citado 2020 Feb 15]; 10(2):135- 41. Disponible en: https://www.researchgate.net/profile/Jose_Restrepo/publication/238794686_Dermatomiositispolimiositis/links/5407603c0cf23d9765a8768d.pdf.
Malik A, Hayat G, Kalia JS, Guzman MA. Miopatías inflamatorias idiopáticas: abordaje clínico y manejo. Front Neurol [Internet]. 2016 [citado 2020 Feb 15]; 7:64. DOI: https://doi.org/10.3389/fneur.2016.00064.
Gil-Moreno MJ, Marasescu R, Camacho-Castañeda FI, Benito-Parra L. Polimiositis secundaria a un linfoma no Hodgkin. Rev Neurol [Internet]. 2017 [citado 2020 Feb 15]; 64: 334-6. Disponible en: https://www.researchgate.net/publication/315784452_Polimiositis_secundaria_a_un_linfoma_no_Hodgkin
Acosta I, Matamala JM, Jara P, Pino F, Gallardo A, Verdugo R. Miopatías inflamatorias idiopáticas: una mirada actualizada al diagnóstico y el manejo. Rev méd Chile [Internet]. 2019 [citado 2020 Feb 15]; 147(3):342-55. DOI: https://doi.org/10.4067/S0034-98872019000300342.
Sasaki H, Kohsaka H. Current diagnosis and treatment of polymyositis and dermatomiositis. Modern Rheumatology [Internet]. 2018 [citado 2020 Feb 16]; 28(6):913-21. DOI: https://doi.org/10.1080/14397595.2018.1467257.
Unit of Biostatistics, Karolinska Institutet, Stockholm, Sweden. Classification Criteria for Idiopathic Inflammatory Myopathies [Internet]. [citado 2020 Feb 16]. Disponible en: http://www.imm.ki.se/biostatistics/calculators/iim/.
Buchbinder R, Forbes A, Hall S, Dennett X, Giles G. Incidence of malignant disease in biopsy-proven inflammatory myopathy. A population-based cohort study. Ann Intern Med [Internet]. 2001 [citado 2020 Feb 16];134(12):1087-95. DOI: https://doi.org/10.7326/0003-4819-134-12-200106190-00008.
Yang Z, Lin F, Qin B, Liang Y, Zhong R. Polymyositis/ dermatomyositis and malignancy risk: a metaanalysis study. J Rheumatol [Internet]. 2015 Feb [citado 2020 Feb 16];42(2):282-91. DOI: https://doi.org/10.3899/jrheum.140566.
Olazagasti JM, Baez PJ, Wetter DA, Ernste FC. Cancer Risk in Dermatomyositis: A Meta-Analysis of Cohort Studies. Am J Clin Dermatol [Internet]. 2015 [citado 2020 Feb 16]; 16 (2): 89-98. DOI: https://doi.org/10.1007/s40257-015-0120-1.
Findlay AR, Goyal NA, Mozaffar T. An overview of polymyositis and dermatomyositis. Muscle Nerve [Internet]. 2015 [citado 2020 Abr 30];51(5):638-56. DOI: https://doi.org/10.1002/mus.24566.
Selva A, Trallero E. Miopatías inflamatorias. Dermatomiositis, polimiositis y miositis con cuerpos de inclusión. Reumatol Clin [Internet]. 2008 [citado 2020 Abr 30];4(5):197-206. DOI: https://doi.org/10.1016/S1699-258X(08)72464-1.
Hochberg MC, Feldman D, Stevens MD. Adult onset polymyositis/ dermatomyositis: an analysis of clinical and laboratory features and survival in 76 patients with a review of literature. Sem Arthritis Rheum [Internet]. 1986 [citado 2020 May 09];15:168-78. DOI: 10.1016/0049-0172(86)90014-4.
Lundberg IE, Tjärnlund A, Bottai M, Werth VP, Pilkington C, Visser M, et al. European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis [Internet]. 2017 [citado 2020 May 09];76(12):1955- 64. DOI: https://doi.org/10.1136/annrheumdis-2017-211468.
Skuk D, Mesa M, Pizzarossa C, Medici M. La biopsia muscular en las miopatías inflamatorias idiopáticas. Rev Med Uruguay [Internet]. 1995 [citado 2020 May 09]; 11:99-104. Disponible en: https://www.rmu.org.uy/revista/1995v2/art3.pdf.
Shabaneh Al-Tamimi HA, McDonald R. Elevated alanine aminotransferase levels associated with polymyositis: can this be due to muscle injury? J Clin Rheumatol [Internet]. 2008 [citado 2020 Jul 17];14(6):363-4. DOI: https://doi.org/10.1097/RHU.0b013e318190b4a6. PMID: 19033872.
Qiang JK, Kim WB, Baibergenova A, Alhusayen R. Risk of Malignancy in Dermatomyositis and Polymyositis: A Systematic Review and Meta-Analysis. J Cutan Med Surg [Internet]. 2017 [citado 2020 Ago 08];21(2):131-136. DOI: https://doi.org/10.1177/1203475416665601.
Lana HE, Lana JE, Córdova OE. Polimiositis: a propósito de un caso. Rev UNIANDES Cienc Salud. 2020; 3(2):456-467.
Gómez LE, Pérez BG, Tafoya RF, Navarro HQ. Polimiositis y serositis. Reporte de un caso. Med Int Mex 2011;27(2):190-192.
Gaston O, Malvino E, Loughlin D, Lopez J, Nitsche A, Cueva, F. Polimiositis con incapacidad ventilatoria e insuficiencia respiratoria. Medicina (Buenos Aires). [Internet]. 2003 [citado 2020 Oct 20]; 63:413-416. Disponible en: http://www.scielo.org.ar/scielo.php?script=sci_arttext&pid=S0025-76802003000500009&lng=es.
Bautista M WA, Reyes S E, Mora C, Guzmán V CM, Londoño P J, Varela P, et al. Indicaciones y utilidad de la inmunoglobulina por vía intravenosa en el manejo de polimiositis refractaria. Reporte de caso y revisión de la literatura. Revista Med [Internet]. 2010 [citado 2020 Oct 20]; 18(2): 241-7. DOI: https://doi.org/10.18359/rmed.1317.
Sierra JL, Toro G, Chalem F. Polimiositis Subaguda. Observaciones clinicopatológicas. Acta Médica Colombiana. 1980;5(3):439-446
Reyes JE, Solis F, González CL. Taquicardia supraventricular como manifestación inicial de polimiositis. Reporte de caso [Internet]. Arch. Cardiol. Méx. 2020 [citado 2020 Nov 20];91(2):235-237. DOI: https://doi.org/10.24875/acm.20000054.
Mañas MD, Marchán E, Calderón P, Lara P. Polimiositis y dermatomiositis como debut de carcinoma de esófago. An Med Interna [Internet]. 2007 [citado 2020 Oct 20];24(5):254–255. Disponible en: http://scielo.isciii.es/scielo.php?script=sci_ arttext&pid=S0212-71992007000500012&lng=es&tlng=es
Domínguez ML, Rayo JI, Serrano J, Sánchez R, Infante JR, García L, et al. Polimiositis paraneoplásica asociada a carcinoma pulmonar: diagnóstico por PET-TAC. Rev Esp Med Nucl [Internet]. 2011[citado 2021 Ene 31];30(3):187–90. DOI: https://doi.org/10.1016/j.remn.2010.11.002.
Burguete-Torres A, González-Guerrero JF, Vidal-Gutiérrez O. Polimiositis paraneoplásica asociada a cáncer de mama: reporte de un caso. J. cancerol [Internet]. 2018 [citado 2021 Mar 01];5(3):103- 107. Disponible en: http://www.journalofcancerology.com/pdf/p4422AX181_JoC%203_13_p-103-107.pdf
Gagnier JJ, Kienle G, Altman DG, Moher D, Sox H, Riley D, et al. The CARE Guidelines: Consensus-based Clinical Case Reporting Guideline Development. J Med Case Reports [Internet]. 2013 [citado 2021 Mar 01];2(5):38-43. DOI: https://doi.org/10.1186/1752-1947-7.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2022 Médicas UIS